AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7508396
Drug: 960 mg
RxNorm normalized name: glycerin 960 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg cotrimoxazole (group A)
Trial: 2730051
Drug: Juzentaiho-to (JTT)
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juzentaiho-to (JTT) combined with chemoendocrine therapy
Trial: 2730051
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy only
Trial: 807995
Drug: Flexical diet
RxNorm normalized name: Flexira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexical diet (semi‐hydrolyzed diet: 10 g % casein hydrolsate; 14 g % triglycerides, 20% of which medium chain; 66% disaccharides)
Trial: 31161580
Drug: +O-desmethyltramadol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +O-desmethyltramadol (200 mg extended-release tablets)
Trial: 29250545
Drug: Simvastatin (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (preoperative and postoperative administration)
Trial: 25450879
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m² and etoposide 100 mg/m² intravenously on days 1 to 3 (control arm)
Trial: 25450879
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m² and etoposide 100 mg/m² combined with bevacizumab 7.5 mg/kg intravenously on day 1 (experimental arm)
Trial: 19761721
Drug: Subcutaneous epoietin-beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Subcutaneous epoietin-beta (0.3 ml = 4000 IU)
Trial: 19761721
Drug: Subcutaneous darbepoietin-alpha
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous darbepoietin-alpha (0.5 ml = 20 microg)
Trial: 19761721
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (0.3 ml)
Trial: 19761721
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (0.5 ml)
Trial: 19761721
Drug: Subcutaneous epoietin-beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Subcutaneous epoietin-beta
Trial: 19761721
Drug: Subcutaneous darbepoietin-alpha
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous darbepoietin-alpha
Trial: 15293466
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of traditional Chinese medicine and western medicine with massage and functional exercise (trial group)
Trial: 15293466
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine and western medicine without massage and functional exercise (control group)
Trial: 11062863
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of zolpidem (ZLP)
Trial: 11062863
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of zopiclone (ZPC)
Trial: 8405631
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol transdermally 0.05 mg/day on days 1‐24 and medroxyprogesterone acetate 10 mg/day orally on days 15‐24 (sequential schedule)
Trial: 8405631
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol transdermally 0.05 mg/day and medroxyprogesterone acetate 2.5 mg/day orally on days 1‐24 (continuous schedule)
Trial: 8405631
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol 0.05 mg/day continuously (in patients who had total abdominal hysterectomy+bilateral salphingooopherectomy)
Trial: 2945332
Drug: Diltiazem (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (1.0 mg administered intracoronarily, distal from the stenosis)
Trial: 31247504
Drug: Opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid agonist treatment (OAT)
Trial: 30621471
Drug: Guluronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guluronic acid (G2013) 500 mg orally twice a day for 12 weeks
Trial: 25068947
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 10 mg/kg intravenously 5 min before skin incision
Trial: 23297844
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D3 supplementation (600 mg elemental calcium and 125 IU vitamin D3) with energy-restricted diet (‐500 kcal/d)
Trial: 19131454
Drug: Subsidised nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsidised nicotine replacement therapy (NRT) plus multisession counselling from the quitline
Trial: 14749454
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (2 g orally per day)
Trial: 11705818
Drug: Conivaptan 20
RxNorm normalized name: conivaptan 20 mg/100 mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 20 mg
Trial: 11705818
Drug: Conivaptan 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 40 mg
Trial: 11705818
Drug: Conivaptan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 10 mg
Trial: 9237061
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplementation with 2 g calcium per day
Trial: 9237061
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplementation with 3.8 g of ispaghula husk
Trial: 2884081
Drug: Ketotifen 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 2.0 mg
Trial: 18656765
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone injection
Trial: 18656765
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (lidocaine)
Trial: 9603138
Drug: Zileuton (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (600 mg)
Trial: 8310508
Drug: 33B3.1 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33B3.1 (10 mg/day)
Trial: 8310508
Drug: ATG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (1 mg/kg/day)
Trial: 2449506
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vancomycin infused over 1 h
Trial: 2449506
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg vancomycin infused over 1 h
Trial: 31161343
Drug: Lacunar infarct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacunar infarct with concurrent embolic infarcts
Trial: 29555621
Drug: Mobile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobile Insulin Titration Intervention (MITI) program
Trial: 28919708
Drug: AOS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOS group (AG, oral administration 10‐mg AOS daily)
Trial: 28919708
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG, placebo daily)
Trial: 19264879
Drug: Home-based Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based Behavioral Family Systems Therapy (BFST)
Trial: 15585437
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 7.5 mg
Trial: 9549739
Drug: Intrathecal opioids
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal opioids (morphine and sufentanil) administered at L3-L4 after induction of anaesthesia
Trial: 9549739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (inhalation and intravenous narcotic anaesthesia)
Trial: 8559866
Drug: Tricyclic Antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic Antidepressant Medication
Trial: 2713219
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (1 g)
Trial: 2713219
Drug: Oral chloramphenicol
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloramphenicol (500 mg)
Trial: 30418227
Drug: Antibiotics without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics without L-carnitine (control)
Trial: 28641912
Drug: Spirited Life
RxNorm normalized name: TURPENTINE SPIRITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirited Life intervention (2-year multicomponent health intervention including personal goal setting, monthly health coaching, online weight loss intervention, small grant, and workshops)
Trial: 21623982
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 mg administered 30 min before bedtime for 7 days
Trial: 16792770
Drug: Efalizumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 1.0 mg kg‐1 once weekly for 12 weeks
Trial: 12125616
Drug: Testosterone injections
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injections
Trial: 1287015
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of famotidine (Group 3)
Trial: 1287015
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of famotidine (Group 6)
Trial: 1287015
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of diphenhydramine (Group 2)
Trial: 1287015
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (Group 1)
Trial: 4075934
Drug: Maternal caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal caffeine ingestion (500 mg/day)
Trial: 30165610
Drug: Canakinumab 50
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months
Trial: 18453793
Drug: 8-item medication
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-item medication adherence scale
Trial: 12649700
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg bid
Trial: 11400948
Drug: Thalidomide (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200-800 mg/day)
Trial: 9489600
Drug: Valaciclovir, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir, 1000 mg, given alone
Trial: 9489600
Drug: Valaciclovir, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir, 1000 mg, given with digoxin
Trial: 9489600
Drug: Digoxin given
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin given with valaciclovir (1000 mg three times/day for 8 days)
Trial: 3361221
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg twice daily
Trial: 29098392
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (6 µg/kg/h over 10 min followed by 0.2‐0.7 µg/kg/h)
Trial: 29098392
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model)
Trial: 16441950
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (50 mg/d)
Trial: 6282434
Drug: MER (methanol-extraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MER (methanol-extraction residue of Bacillus Calmette-Guerin) 400 mcg intradermally every six weeks
Trial: 30536595
Drug: sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 200 mg and 400 mg
Trial: 10955425
Drug: Monitoring plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring plasma glucose up to four times daily
Trial: 6337655
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose bolus 6‐methylprednisolone (BMPr) at 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, then tapered to 1 mg/kg/day.
Trial: 6337655
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose bolus 6‐methylprednisolone (BMPr)
Trial: 30064027
Drug: Tumor Treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Treating Fields (TTF) therapy
Trial: 24756515
Drug: Lorazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.1 mg/kg IV, repeat at 5 minutes if necessary)
Trial: 24756515
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg/kg IV, repeat at 5 minutes if necessary)
Trial: 24756515
Drug: Lorazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.1 mg/kg IV)
Trial: 12524668
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose given to fed subjects
Trial: 12524668
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose given to 4-day-fasted subjects
Trial: 12524668
Drug: 33 g
RxNorm normalized name: lancets 33 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 g glucose in OGTT for 13-hour-fasted subjects
Trial: 12524668
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose in OGTT for 13-hour-fasted subjects
Trial: 10472349
Drug: Docetaxel/Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/Irinotecan at dose level 1 (20/25 mg/m2)
Trial: 10472349
Drug: Docetaxel/Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/Irinotecan at dose level 2 (20/40 mg/m2)
Trial: 10472349
Drug: Docetaxel/Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/Irinotecan at dose level 3 (25/55 mg/m2)
Trial: 10472349
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Docetaxel/Irinotecan with radiotherapy)
Trial: 2060716
Drug: High fasting
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fasting plasma insulin concentration and low 2-h plasma insulin concentration after a glucose load
Trial: 22760800
Drug: 0.1% riboflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% riboflavin (w/v) eyedrops in 20% dextran solution for 1 month
Trial: 17993041
Drug: Modafinil 200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200, 300, or 400 mg once daily for up to 12 weeks
Trial: 15598674
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/d, n = 25)
Trial: 15598674
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg three times daily, n = 27)
Trial: 8427821
Drug: Topical betamethasone-17-valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical betamethasone-17-valerate
Trial: 3669078
Drug: No‐Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No‐Treatment
Trial: 31043129
Drug: High-load resistance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1RM)
Trial: 31043129
Drug: Low-load resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-load resistance training with partial blood flow restriction (LL-BFR, e.g. 20% 1RM)
Trial: 28238522
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus endovascular treatment
Trial: 21813857
Drug: DENV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV vaccine (34 subjects; four received 1/10th dose)
Trial: 21813857
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (17 subjects; dose 1: live varicella; dose 2: Haemophilus influenzae type b)
Trial: 19356272
Drug: Regular-energy orangeade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-energy orangeade with large sips (20 g/sip)
Trial: 19356272
Drug: Regular-energy orangeade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-energy orangeade with small sips (5 g/sip)
Trial: 19356272
Drug: No-energy orangeade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-energy orangeade with large sips (20 g/sip)
Trial: 19356272
Drug: No-energy orangeade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-energy orangeade with small sips (5 g/sip)
Trial: 8995749
Drug: 1 alpha
RxNorm normalized name: antiCD11 alpha
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 alpha (OH)‐vitamin D2, 4 micrograms/day or 4 micrograms thrice weekly, adjusted over 12 weeks
Trial: 3680575
Drug: Microencapsulated KCl
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microencapsulated KCl capsule preparation
Trial: 3680575
Drug: Wax-matrix formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax-matrix formulation
Trial: 3680575
Drug: New microencapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New microencapsulated KCl tablet preparation
Trial: 27143690
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg weekly)
Trial: 21360491
Drug: Rituximab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (2 × 500 mg intravenously)
Trial: 18165599
Drug: Ropivacaine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 90 mg (9 mL), morphine 4 mg (10 mL), and ketorolac 30 mg (1 mL) (total volume 20 mL)
Trial: 20880596
Drug: Saline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (20 mL)
Trial: 18165599
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac 30 mg (1 mL)
Trial: 18165599
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline (1 mL)
Trial: 12948794
Drug: Carbocaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocaine (10 mg/ml)
Trial: 7521662
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow transplantation (ABMT) with high-dose melphalan, and additional treatments including fractionated total body irradiation, hemi-body irradiation, and high-dose etoposide.
Trial: 2511684
Drug: 5 x
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x 2.5 mg isosorbide dinitrate (ISDN)
Trial: 2511684
Drug: 5 x
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x 40 mg isosorbide dinitrate (ISDN)
Trial: 2511684
Drug: Low-dose ISDN
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ISDN
Trial: 2511684
Drug: High-dose ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ISDN
Trial: 128287
Drug: Measles-mumps-rubella trivalent
RxNorm normalized name: MEASLES/MUMPS/RUBELLA VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles-mumps-rubella trivalent vaccine
Trial: 26520396
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg corifollitropin alfa
Trial: 23604689
Drug: Zoledronate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (4 mg annually)
Trial: 21476064
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg single oral dose)
Trial: 17374042
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Coping Skills Therapy (CBCST)
Trial: 15338385
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (stationary biking 30 min five times weekly)